1. Home
  2. EDAP vs LUNG Comparison

EDAP vs LUNG Comparison

Compare EDAP & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

HOLD

Current Price

$3.73

Market Cap

75.5M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.01

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDAP
LUNG
Founded
1979
1995
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.5M
63.6M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
EDAP
LUNG
Price
$3.73
$2.01
Analyst Decision
Buy
Buy
Analyst Count
3
7
Target Price
$8.50
$6.81
AVG Volume (30 Days)
80.7K
700.2K
Earning Date
11-06-2025
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$74,853,925.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
$2.67
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
0.61
15.59
52 Week Low
$1.21
$1.31
52 Week High
$4.00
$9.37

Technical Indicators

Market Signals
Indicator
EDAP
LUNG
Relative Strength Index (RSI) 68.40 42.62
Support Level $3.53 $2.18
Resistance Level $3.45 $2.39
Average True Range (ATR) 0.29 0.16
MACD 0.05 -0.06
Stochastic Oscillator 76.92 4.84

Price Performance

Historical Comparison
EDAP
LUNG

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: